All questions
Safety: Repatha (evolocumab) in cardiovascular event risk reduction 4 questions · 1 source
Safety questions that apply to every indication of Repatha are on Repatha (evolocumab), all indications: Safety .
Safety evidence Does Repatha affect memory or cognitive function (EBBINGHAUS)? Note: In FOURIER, patients with established cardiovascular disease on statin therapy received REPATHA 140 mg every 2 weeks or 420 mg once monthly, or placebo.
Side effects What are the most common side effects of Repatha in cardiovascular outcomes trials? “Trial 1 (FOURIER)
In a double-blind, randomized, placebo-controlled CV outcomes trial in patients with established
atherosclerotic cardiovascular disease (ASCVD), 27,525 patients received at least one dose of REPATHA
or placebo [see Clinical Studies (14)]. The mean age was 62.5 years (range: 40 to 86 years), 45% were 65
years or older, 9% were 75 years or older, 25% female, 85% White, 10% Asian, and 2% Black or African
American; 8% identified as Hispanic or Latino ethnicity. Patients were exposed to REPATHA or placebo
for a median of 24.8 months; 91% of patients were exposed for ≥ 12 months, 54% were exposed for ≥ 24
months and 5% were exposed for ≥ 36 months.
The safety profile of REPATHA in this trial was generally consistent with the safety profile described
above in the 12- and 52-week controlled trials involving patients with hypercholesterolemia. Common
adverse reactions (> 5% of patients treated with REPATHA and occurring more frequently than placebo)
included diabetes mellitus (8.8% REPATHA, 8.2% placebo), nasopharyngitis (7.8% REPATHA, 7.4%
placebo), and upper respiratory tract infection (5.1% REPATHA, 4.8% placebo).” (opens the source at this quote in a new tab) Copy Flag
Note: The second passage concerns Trial 2 (VESALIUS-CV), in patients at high cardiovascular risk without a prior myocardial infarction or stroke.
Does Repatha increase the risk of diabetes? Note: These figures are from FOURIER, a placebo-controlled trial in patients with established atherosclerotic cardiovascular disease with a median exposure of 24.8 months.
What did VESALIUS-CV show about Repatha's long-term safety?